Loading clinical trials...
Loading clinical trials...
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects With Sickle Cell Disease
Conditions
Interventions
IMR-687
Placebo
Locations
49
United States
University of Alabama at Birmingham School of Medicine - 1917 Clinic
Birmingham, Alabama, United States
Arkansas Primary Care Clinic
Little Rock, Arkansas, United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
Center For Inherited Blood Disorders
Santa Ana, California, United States
The Oncology Institute Long Beach
Whittier, California, United States
University of Connecticut Health Main Building
Farmington, Connecticut, United States
Start Date
August 13, 2020
Primary Completion Date
March 2, 2022
Completion Date
May 4, 2022
Last Updated
May 15, 2025
NCT05170412
NCT06526117
NCT06665997
NCT07431398
NCT07222475
NCT05377372
Lead Sponsor
Cardurion Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions